Samsung Life Science invests in US biotech firm Latus Bio
Samsung Life Science Fund, managed by Samsung Group’s venture investment arm, has invested in US biotechnology firm Latus Bio Inc. during the ...
Samsung targets gene therapy sector through US investments
Samsung Group is targeting the gene therapy business through investments in US biotechnology companies as the leading South Korean conglomerate is s...
Daewoong gets stem cell facility license in Indonesia
South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...
MedPacto gets FDA OK for colorectal cancer drug clinical trial
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...
S.Korea’s GC Cell targets global cell therapy CDMO business
GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...
Dong-A ST, UMass to jointly research for gene therapy
South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...
NKMax to perform first tests on dementia cell therapy in US
NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...
HLB gets global rights to Chinese liver cancer drug
South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...
NKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
SK becomes top shareholder of US contract drug maker CBM
SK Pharmteco Co., a South Korean contract development and manufacturing organization (CDMO), said on Wednesday it has secured management rights of t...
Gencurix joins US gov't Cancer Moonshot project
South Korean cancer molecular diagnostics company Gencurix Inc. announced on Monday that it joins US President Joe Biden's cancer-conquering project...
SK Biopharm eyes Asia's No.1 spot in radioactive drug market
South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...
GI Innovation seeks to license allergy therapy to Japan in 2023
South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...
Neurophet strives to be first mover in fight against Alzheimer’s
Neurophet Inc., a South Korean startup developing artificial intelligence-powered medical solutions for brain diseases, is striving to make a breakt...
Welt gets second digital therapeutic device approval in S. Korea
South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...
Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer
South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...
Verismo's CAR-T therapy designated fast-track status by FDA
Verismo Therapeutics, a US affiliate of South Korean pharmaceutical firm HLB Co., has received fast-track designation from the US Food and Drug Admi...
US affiliate of Korea's cell therapy company NK Max eyes NYSE listing in 3Q
NKGen Biotech, the US affiliate of South Korea's natural killer (NK) cell therapy developer NK Max, on Friday said it signed a letter of intent (LOI) ...
Korea's ST Pharm completes new R&D hub for gene therapy
ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&...
HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China
South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...
GC Cell's AB-101 NK therapy achieves FDA fast-track status
South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US F...
Kolon signs MOU with Hanyang Univ. to develop gene therapy treatments
Kolon Industries Inc.'s Future Technology Institute said on Thursday that it had signed a memorandum of understanding with the Hanyang University In...
GI Cell wins approval for human cell management from Korean regulator
GI Cell, a South Korean developer of immune cell therapy products, received a human cell and others management license from South Korean regulatory,...
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Samsung Biologics in CDO deal talks with global pharma firm
FRANKFURT – Samsung Biologics Co., the world’s largest contract drugmaker, is in talks to develop medicines for a global pharmaceutical ...
K-bio firms embrace gene therapy CDMO as Samsung looks the other way
South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanis...
LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., has received the US Food and Drug Administration’s approval for phase 1 cli...
Kolon Life inks technology transfer deal with Juniper Biologics
South Korea’s pharmaceutical company Kolon Life Science Inc. signed a technology export deal worth up to 723.4 billion won ($589.1 million) wi...
SK Bioscience seeks multi-billion-dollar M&As, eyes gene therapy sector
SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand it...
Samsung’s Life Science Fund invests in US biotech Jaguar Gene Therapy
Samsung Group’s 150 billion won ($124 million) Life Science Fund launched last year has chosen a leading US gene therapy development company a...
